Regeneron Pharmaceuticals Inc (REGN)

368.16
3.72 1.02
NASDAQ : Health Care
Prev Close 364.44
Open 364.76
Day Low/High 364.44 / 373.48
52 Wk Low/High 329.09 / 605.93
Volume 943.79K
Avg Volume 989.30K
Exchange NASDAQ
Shares Outstanding 105.47M
Market Cap 38.44B
EPS 6.20
P/E Ratio 53.20
Div & Yield N.A. (N.A)

Latest News

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow 20,000 came agonizingly close on Friday, but building momentum flagged in the final moments of the trading session.

Dow Teases Wall Street With 20,000 Milestone but Backs Off

Dow Teases Wall Street With 20,000 Milestone but Backs Off

The Dow Jones Industrial Average backs away from its 20,000 milestone again on Friday after coming within a point of the level earlier in the session.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks rise Friday, though unsettled trading made gains uncertain, after wage growth in December raises the chances for a few rate hikes this year.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Use Regeneron's Current Weakness to Go Long

Use Regeneron's Current Weakness to Go Long

Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock futures turn higher Friday after the Labor Department says the U.S. added 156,000 jobs in December.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures trade slightly lower Friday ahead of the U.S. jobs report for December, the last under the Obama presidency.

Sanofi Investors Have Worst Day in Six Months

Sanofi Investors Have Worst Day in Six Months

Praluent Infringes on Amgen's patents for rival drug, Repatha, a ruling says.

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job

Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job

Biogen promoted its current Chief Commercial Officer Michel Vounatsos to become the biotech company's next CEO.

White House Kills Plan for Drug Price Cap

White House Kills Plan for Drug Price Cap

Pelosi, Schumer and nearly everyone else had asked Obama to deep-six the deal.

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Here are Friday's top research calls, including upgrades for Eli Lilly, Regeneron and GE, and downgrades for Nordstrom, Coca-Cola, Apache and Duke Energy.

Help Wanted: Large-Cap Biotech CEOs Capable of Soothing Raw Nerves of Health Care Investors in 2017

Help Wanted: Large-Cap Biotech CEOs Capable of Soothing Raw Nerves of Health Care Investors in 2017

For health care investors, CEO vacancies at two of the six big-cap biotech companies aren't helping sentiment heading into 2017.

Ophthotech Plunges on Eye-Drug-Study Failure

Ophthotech Plunges on Eye-Drug-Study Failure

Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.

Jim Cramer -- Ophthotech's Loss a Cautionary Win for Regeneron

Jim Cramer -- Ophthotech's Loss a Cautionary Win for Regeneron

Shares of Ophthotech are plunging after the company's Phase 3 results failed to meet specific endpoints.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.